COMMUNIQUÉS West-GlobeNewswire

Geron to Host Analyst and Investor Meeting and Webcast on December 19, 2017
06/12/2017
MENLO PARK, Calif., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN ) today announced that the company’s analyst and investor meeting to discuss imetelstat clinical data will take place in New York, N. [...]
Summit Therapeutics plc : 3rd Quarter Results
06/12/2017
Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED 31 OCTOBER 2017 AND OPERATIONAL PROGRESS Oxford, UK, 6 December [...]
Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Progress
06/12/2017
OXFORD, United Kingdom, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM)(NASDAQ: SMMT ), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and C. [...]
Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering
06/12/2017
NEW YORK, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM ), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]
Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock
06/12/2017
CAMBRIDGE, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT ), a leading genome editing company, today announced the pricing of an underwritten offering of 1,970,000 shares of its common [...]
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial
06/12/2017
-- Statistically significant improvement in the relative decrease in liver fat in patients treated with MGL-3196 compared with placebo, determined by magnetic resonance imaging-estimated proton density fat fraction (MRI [...]
Interim results of first-ever global survey show people with type 2 diabetes underestimate their cardiovascular risk
06/12/2017
Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes 1 1 in 3 respondents considered themselves to be at low risk of (CVD) 2 1 in 6 respondents had never discussed type [...]
Summit, Santhera, Catabasis and Duchenne UK to Host DMD Awareness Day
06/12/2017
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day Liestal, Switzerland, Oxford, UK, Cambridge, Mass., 6 December 2017: Santhera [...]
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
06/12/2017
LIESTAL, Switzerland, OXFORD, England and CAMBRIDGE, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Santhera Pharmaceuticals (SIX:SANN) , Summit Therapeutics (NASDAQ: SMMT ) (AIM:SUMM) , Catabasis Pharmaceuticals (NASDAQ: [...]
Tabula Rasa HealthCare Announces Pricing of Sale of Shares of Common Stock
06/12/2017
MOORESTOWN, N.J., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC ) (“TRHC”), a healthcare technology company optimizing medication safety by deploying new medication risk mitigation digital [...]
3D Signatures Inc. Announces the Closing of its Non-Brokered Private Placement
06/12/2017
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V: DXD ) (OTCQB:TDSGF) (FSE:3D0) (the " Company " or " 3DS ") [...]
Pascal Announces the Appointment of a New Director, Dr. Graeme I. Bell
06/12/2017
VANCOUVER, B.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSX VENTURE:PAS), a biotechnology company that specializes in cancer drug discovery and development, today [...]
Beleave Closes $9.95 Million Non-Brokered Private Placement of Units
06/12/2017
TORONTO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. (" Beleave " or the " Company ") (CSE:BE) (OTCQX:BLEVF) is pleased to announce the completion of a non-brokered private placement (the " Non-Brokered Offering ") [...]
Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study
05/12/2017
PHILADELPHIA, Pa. and OXFORD, UK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, will have updated data from its completed pilot study 1 of NY [...]
MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte
05/12/2017
ROCKVILLE, MD, Dec. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]
Editas Medicine, Inc., Announces Offering of Common Stock
05/12/2017
CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT ), a leading genome editing company, today announced that it intends to offer and sell $50,000,000 of shares of its common stock in [...]
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA ) announced today that on November 27, 2017, the Compensation Committee of the Board of Directors approved, [...]
HealthEquity Reports Third Quarter Ended October 31, 2017 Financial Results
05/12/2017
Highlights of the third quarter include: Revenue of $56.8 million, an increase of 31% compared to Q3 FY17. Net income of $10.5 million, an increase of 74% compared to Q3 FY17. Net income per diluted share of $0.17 [...]
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
05/12/2017
LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its [...]

Pages